<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133822</url>
  </required_header>
  <id_info>
    <org_study_id>0184-2004</org_study_id>
    <secondary_id>RIS-EMR-4005</secondary_id>
    <nct_id>NCT00133822</nct_id>
  </id_info>
  <brief_title>Civilian Post-Traumatic Stress Disorder Risperidone Clinical Trial</brief_title>
  <official_title>Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the administration of risperidone is&#xD;
      effective in the treatment of selective serotonin reuptake inhibitor (SSRI)-resistant&#xD;
      post-traumatic stress disorder (PTSD) in civilians.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with PTSD often experience anxiety attacks, nightmares, or repeated unwanted&#xD;
      memories after experiencing or witnessing life-threatening events, such as serious accidents&#xD;
      or natural disasters, or traumatic events such as physical or sexual abuse.&#xD;
&#xD;
      Risperidone has been approved by the Food and Drug Administration for the treatment of&#xD;
      psychotic disorders and has been found helpful for PTSD and depression, but is still&#xD;
      considered investigational for the purposes of this study.&#xD;
&#xD;
      All qualified participants will be started on sertraline (Zoloft) for eight weeks. Patients&#xD;
      who are still symptomatic at the end of this phase, will be invited to join the second&#xD;
      portion of the study where they will be randomly assigned to receive risperidone or placebo&#xD;
      (sugar pill) in addition to the sertraline. Participants will be monitored regularly for&#xD;
      medication effects, adverse events, and PTSD symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of symptoms after 16 weeks</measure>
  </primary_outcome>
  <enrollment>65</enrollment>
  <condition>Post-Traumatic Stress Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline and Risperidone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets criteria for DSM-IV PTSD for a minimum of one month duration&#xD;
&#xD;
          -  Clinician-Administered PTSD Scale (CAPS) score &gt; or = to 50&#xD;
&#xD;
          -  Able to read and complete questionnaires and interviews&#xD;
&#xD;
          -  Negative urine drug screen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Primary psychotic disorder; psychotic disorder; or cognitive disorder.&#xD;
&#xD;
          -  Prominent suicidal or homicidal ideation&#xD;
&#xD;
          -  Alcohol or substance dependence within 3 months of starting study&#xD;
&#xD;
          -  Primary anxiety disorder or bipolar disorder&#xD;
&#xD;
          -  Patients currently being treated with antipsychotic medication&#xD;
&#xD;
          -  Patients in active psychotherapy aimed at PTSD&#xD;
&#xD;
          -  Combat-related PTSD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara O Rothbaum, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center South</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Barbara O. Rothbaum, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Post-Traumatic Stress Disorder</keyword>
  <keyword>Sertraline</keyword>
  <keyword>Risperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

